| editorial | Q871232 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1023/A:1008327527877 |
| P698 | PubMed publication ID | 10761746 |
| P2093 | author name string | J Verweij | |
| P2860 | cites work | Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center | Q70891316 |
| Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials | Q73668726 | ||
| Responses and toxic deaths in phase I clinical trials | Q37863716 | ||
| Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents | Q40864715 | ||
| Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998. | Q48584188 | ||
| Response rates, duration of response, and dose response effects in phase I studies of antineoplastics | Q67899179 | ||
| P433 | issue | 2 | |
| P921 | main subject | phase I clinical trial | Q5452194 |
| P304 | page(s) | 131-132 | |
| P577 | publication date | 2000-02-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | The prognosis of prognostic factors in phase I clinical trials | |
| P478 | volume | 11 |
| Q51710026 | A predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic. |
| Q36288003 | Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin |
| Q30336409 | Safety issues in cell-based intervention trials. |
Search more.